Cutler Group’s Protalix BioTherapeutics PLX Stock Holding History

Cutler Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,067	Closed	-$8K	–	5864
2021 Q4	$8K	Sell	10,067 -1,200	-11%	-$1.26K	﹤0.01%	3878
2021 Q3	$14K	Buy	11,267 +4,367	+63%	+$6.64K	﹤0.01%	3661
2021 Q2	$13K	Buy	+6,900	New	+$23.7K	﹤0.01%	3690

Other funds holding PLX

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Cutler Group's PLX Position: Q1 2022 in Review

Cutler Group sold out of Protalix BioTherapeutics (PLX) in Q1 2022, closing a stake of 10,067 shares — an estimated $8K sold.

Cutler Group first reported a position in PLX in Q2 2021 and held it in 3 quarters. The position peaked at $14K in Q3 2021. 32 funds tracked by Wall St. Rank hold PLX as of Q1 2022.

Cutler Group reported no remaining Protalix BioTherapeutics position as of Q1 2022 after selling out during the quarter.
Cutler Group sold 10,067 Protalix BioTherapeutics shares in Q1 2022, an estimated $8K.
Cutler Group first reported a position in Protalix BioTherapeutics in Q2 2021 and held it in 3 quarters.
Cutler Group's Protalix BioTherapeutics position peaked at $14K in Q3 2021.
32 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.